maintenance therapy after allogeneic hsct in mds
Published 3 years ago • 131 plays • Length 6:20Download video MP4
Download video MP3
Similar videos
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
5:43
pre- and post-allohsct treatment in mds
-
2:50
conditioning intensity and genomics: relapse after allogeneic transplant in mds
-
1:29
mutational profiles of mds patients undergoing allo-hsct
-
1:20
the current standard of care for patients with lower-risk mds
-
2:15
optimizing transplantation for mds
-
3:02
the effects of maintenance therapy on real-world outcomes for patients with ndmm
-
2:27
gilteritinib maintenance after allogeneic transplantation in flt3-mutated aml
-
2:35
methods of optimizing transplantation in mds
-
1:48
do all patients require maintenance therapy following allosct?
-
4:28
approaching patients with mds and aml who relapse after allosct & strategies to prevent relapse
-
2:02
oral azacitidine maintenance in aml with mds-related changes: insights from quazar aml-001
-
2:52
the evolving role of maintenance therapy post-asct in mm
-
2:43
novel therapies in the future of mds treatment
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
1:18
update on immunotherapy in mds
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
2:03
maintenance therapy in aml
-
5:00
phase i study of ven/aza maintenance therapy following ven/flubu2 ric allosct in high-risk mds/aml